Interacciones de Tobramicina

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (etiqueta de Tobramicina, Interacciones medicamentosas)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (etiqueta de Bumetanida, Interacciones medicamentosas)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (etiqueta de Carboplatino, Interacciones medicamentosas)

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (etiqueta de Dicloxacilina, Interacciones medicamentosas)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (etiqueta de Foscarnet, Interacciones medicamentosas)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (etiqueta de Tobramicina, Interacciones medicamentosas)

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (etiqueta de Gentamicina, Advertencia en recuadro)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (etiqueta de Neomicina, Advertencia en recuadro)

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (etiqueta de Pentamidina, Interacciones medicamentosas)

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED. (etiqueta de Polimixina B, Advertencia en recuadro)

Avoid concomitant use of torsemide and aminoglycoside antibiotics, if possible. (etiqueta de Torasemida, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etiqueta de Ácido zoledrónico, Interacciones medicamentosas)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (etiqueta de Adefovir, Advertencias y precauciones)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (etiqueta de Atracurio, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (etiqueta de Cefepima, Interacciones medicamentosas)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (etiqueta de Cefotaxima, Interacciones medicamentosas)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (etiqueta de Cefotetán, Precauciones)

Aminoglycosides: Increased potential of nephrotoxicity. (etiqueta de Cefoxitina, Interacciones medicamentosas)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (etiqueta de Cefprozilo, Interacciones medicamentosas)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (etiqueta de Ceftazidima, Interacciones medicamentosas)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (etiqueta de Ceftriaxona, Interacciones medicamentosas)

…ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive or synergistic renal impairment… (etiqueta de Ciclosporina, Interacciones medicamentosas)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (etiqueta de Cidofovir, Advertencias)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Efavirenz, lamivudina y tenofovir, Interacciones medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (etiqueta de Emtricitabina, rilpivirina y tenofovir, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (etiqueta de Micofenolato, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (etiqueta de Piperacilina y tazobactam, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (etiqueta de Rocuronio, Interacciones medicamentosas)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (etiqueta de Sirolimus, Advertencias y precauciones)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etiqueta de Tacrolimus, Advertencias y precauciones)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (etiqueta de Tenofovir, Interacciones medicamentosas)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (etiqueta de Toxina botulínica tipo A, Interacciones medicamentosas)

Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation ( 7 ) (etiqueta de Toxina incobotulínica A, Interacciones medicamentosas)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (etiqueta de Toxina onabotulínica A, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (etiqueta de Tobramicina, Interacciones medicamentosas)

The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. (etiqueta de Vancomicina, Advertencias y precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN. (etiqueta de Ampicilina y sulbactam, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (etiqueta de Colistimetato, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (etiqueta de Piridostigmina, Interacciones medicamentosas)

Before therapy with ZEMDRI is instituted, careful inquiry about previous hypersensitivity reactions to other aminoglycosides should be made. (etiqueta de Plazomicina, Advertencias y precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (etiqueta de Vecuronio, Precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

…assess the need for additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of… (etiqueta de Cisatracurio, Interacciones medicamentosas)